Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA commish in demand

This article was originally published in The Gray Sheet

Executive Summary

Senate HELP Committee members urge President Bush to nominate a permanent commissioner "as soon as possible" in Feb. 1 letter. "So that [HHS] Secretary Leavitt can do his job more effectively, you and he need to identify a nominee for FDA commissioner who has demonstrated leadership capabilities, a strong knowledge of science, and an unwavering commitment to promoting and protecting the public health," states the letter, signed by HELP Chair Michael Enzi (R-Wyo.), Ranking Member Ted Kennedy (D-Mass.) and most other committee members. Acting Commissioner Lester Crawford is said to be the President's top candidate for the job (1"The Gray Sheet" Jan. 31, 2005, p. 4)...

You may also be interested in...

FDA Commish Pick Imminent? Crawford Finally May Shed Understudy Role

The White House seems to have selected FDA Acting Commissioner Lester Crawford, PhD/DVM, as its choice to fill the commissioner slot on a permanent basis

Senate Drug Pricing Bill Lowers Manufacturer Discounts In Part D Catastrophic Phase

Revised bill released by the US Senate Finance Committee adjusts the manufacturer discount program in Medicare Part D and includes new provisions aimed at easing beneficiary cost sharing obligations.

Performance Criteria Issued On Magnetic Resonance Coils In New FDA Draft Guidance

Through a draft guidance, the US agency has established performance criteria for magnetic resonance coils, making the devices eligible for the standards-based Safety and Performance Based Pathway.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts